Vaccines Franchise Medical Manager
About the job
- Industry experience in medical affairs (field or office) and/or clinical experience is mandatory, ideally focused on immunology, vaccinology, epidemiology, public health, or acute medicine/ICU.
- A good understanding of data generation, including clinical development, real-world evidence, and data gaps analysis, is required.
- Ability to act independently with a solutions-oriented, balanced approach to ambiguity is required.
- Ability to communicate effectively, including driving challenging discussions, is required.
- Ability to adapt communication style and channels to healthcare professional communication preferences is required.
- Ability to use omnichannel tools confidently and adapt to new channels is required.
- Participate in and execute the non-promotional medical and scientific strategy for the Influenza and COVID vaccines portfolio/therapeutic area, in partnership with functional franchise leads and aligned with the overall franchise strategy.
- Act as a strategic business partner to the organization, using business acumen.
- Initiate and drive projects that raise standards of care and change clinical practice.
- Lead and drive rapid integrated evidence planning and execution by understanding stakeholder evidence needs and analyzing data gaps.
- Apply deep therapy-area expertise and product knowledge, including competitor data.
- Build collaborative relationships with commercial and cross-functional teams, including marketing, value and access, health economics, regulatory, and clinical teams.
- Cultivate and maintain relationships with external experts.
- Collaborate with above-country colleagues to ensure country involvement and strategic input into global and regional plans.
- Apply an understanding of healthcare systems and their evolution.
- Lead the creation and implementation of medical plans.
- Rapidly assimilate new data and integrate it into the therapy area.
- Create digital educational and scientific content that is timely, relevant, interactive, and innovative.
- Champion the patient voice in developing and implementing medical strategies.
- Influence across networks and coach and mentor team members.
- Develop scientific engagement journeys by bridging channel disconnects to support ongoing engagement and meaningful scientific exchange.
- Share healthcare professional and center unmet needs compliantly with cross-functional teams to inform patient-centric strategy.
- Doctorate-level education, with an MD or equivalent medical degree preferred; a PhD or PharmD is also specified.
- Relevant focus in immunology, vaccinology, epidemiology, public health, or internal medicine with acute medicine/ICU experience is desirable.
About the company
Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.
Company Size
10,001+
Company Stage
IPO
Headquarters
Paris, France
Founded
1973
Get referred to Sanofi
See people who can refer or advise you
Simplify's Take
What believers are saying
- July 10, 2026 FDA approval of Sarclisa Escena created the first on-body cancer injector.
- June 13, 2026 FDA accelerated approval expanded Tzield into recently diagnosed stage 3 T1D.
- Q2 2026 sales grew 17.8% at CER, with Dupixent and Beyfortus leading.
What critics are saying
- Texas sued Sanofi on February 19, 2026 over provider bribery and Medicaid fraud.
- Sanofi sued Pfizer and Moderna on July 15, 2026, extending costly mRNA patent warfare.
- Dupixent concentration makes 2030s patent loss an existential revenue shock.
What makes Sanofi unique
- Dupixent reached €5.2 billion quarterly sales in Q2 2026 across nine indications.
- October 1, 2026, Sanofi and Regeneron added four long-acting antibodies to their Alliance.
- Sanofi's 61-project pipeline spans immunology, rare diseases, vaccines, neurology, and oncology.
Help us improve and share your feedback! Did you find this helpful?
Benefits
- Health Insurance
- Professional Development Budget
- Parental Leave